No reliable evidence shows that the brain releases DMT during dreaming. The idea has become enormously popular in psychedelic culture, but researchers who have looked at the question directly have found that endogenous DMT concentrations in the brain are far too small to produce anything resembling a psychedelic experience. The claim rests more on appealing speculation than on measured biology, and the science that does exist points toward a much less dramatic role for the compound in normal brain function.
Where the Idea Came From
The notion that DMT floods the brain during dreams, birth, and death traces largely to Rick Strassman, a psychiatrist who conducted FDA-approved DMT injection studies at the University of New Mexico in the 1990s. In his 2001 book DMT: The Spirit Molecule, Strassman speculated that the pineal gland might produce and release DMT during REM sleep, at the moment of death, and during mystical experiences. He was careful to frame this as a hypothesis rather than an established fact, but the idea took on a life of its own. It became a staple of podcasts, documentaries, and online psychedelic communities, often repeated as though it were settled science. A 2018 review in the Journal of Psychopharmacology examined these claims and concluded bluntly that scientific evidence is not consistent with the idea that DMT is secreted by the pineal gland during dreaming or near death to produce out-of-body experiences.1SAGE Journals / Journal of Psychopharmacology. N,N-dimethyltryptamine and the pineal gland: Separating fact from myth
DMT Is Made in the Brain, but in Tiny Amounts
One reason the hypothesis sounds plausible is that DMT genuinely is produced inside the mammalian brain. It is not just an exotic plant compound or a lab-synthesized drug. The biosynthetic pathway involves two enzymes: aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT), both of which have been found in brain tissue.2Scientific Reports. Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain In 2019, researchers at the University of Michigan confirmed that living rat brains actively synthesize DMT and that the compound can be detected in brain extracellular fluid. That study was a landmark because it proved endogenous production in neural tissue, not just in peripheral organs like the lungs or liver where INMT had been found earlier.
But “the brain makes DMT” and “the brain makes enough DMT to cause hallucinations” are very different statements. The concentrations detected in brain microdialysate are extremely small. The same 2018 review that debunked the pineal hypothesis noted that the minute concentrations of DMT found in the brain are not sufficient to produce psychoactive effects.1SAGE Journals / Journal of Psychopharmacology. N,N-dimethyltryptamine and the pineal gland: Separating fact from myth To put it plainly, finding a trace of a substance in the brain tells you that the body uses it for something. It does not tell you that the body uses it to generate dream visions.
The Pineal Gland Problem
The pineal gland holds a special place in this story because Strassman singled it out as the likely source of dream-related DMT surges. The gland has a mystical reputation (Descartes famously called it “the seat of the soul”), and its role in producing melatonin gave it a vague association with sleep. But the adult human pineal gland weighs less than 0.2 grams. Its primary job is to produce about 30 micrograms of melatonin per day, a hormone that regulates circadian rhythm through very high-affinity interactions with its receptors.1SAGE Journals / Journal of Psychopharmacology. N,N-dimethyltryptamine and the pineal gland: Separating fact from myth A gland that tiny, already busy making melatonin, would struggle to churn out the milligram-scale quantities of DMT needed to flood serotonin receptors throughout the cortex.
In 2013, researchers did detect DMT in rat pineal gland microdialysate for the first time, confirming that the pineal is at least one site where the compound appears.3PubMed Central. LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate That finding was real and important for understanding the biology, but it did not show that the pineal releases DMT in quantities that would matter perceptually. The gap between “detectable” and “psychoactive” is enormous, and no one has bridged it.
Why the Body Destroys DMT Almost Instantly
Even if some mechanism did release a burst of DMT into the bloodstream or brain, the compound would face an aggressive cleanup crew. DMT is broken down primarily by the enzyme monoamine oxidase A (MAO-A) in the liver, and the process is fast. In human liver fractions, the half-life of DMT at low concentrations was under eight minutes.4PubMed Central. Pharmacokinetics of N,N-dimethyltryptamine in Humans A systematic review of DMT pharmacokinetics confirmed that this rapid metabolism by MAO-A is the main reason DMT’s effects are so brief when injected: the compound is converted into inactive metabolites shortly after entering the bloodstream.5PubMed Central. Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis
This is why ayahuasca, the Amazonian brew that contains DMT, also contains MAO inhibitors from the Banisteriopsis caapi vine. Without those inhibitors blocking the enzyme, oral DMT would be destroyed in the gut and liver before it ever reached the brain in meaningful amounts. The body’s default mode is to neutralize DMT on contact. For endogenous DMT to accumulate to psychoactive concentrations during a normal night’s sleep, something would have to dramatically suppress MAO-A activity at the same time. No one has found evidence that this happens.
What Giving People DMT Actually Does to Sleep
If endogenous DMT were the engine behind dreaming, you might expect that administering DMT or DMT-containing preparations would enhance dream-like brain activity or increase REM sleep. The evidence points in the opposite direction. When healthy volunteers were given ayahuasca during the day and their sleep was recorded that night, the brew suppressed REM sleep. Both the total duration of REM and its percentage of total sleep time decreased, and there was a trend toward longer latency before REM kicked in.6PubMed. Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers Ayahuasca did enhance slow-wave sleep power in the first sleep cycle, which is linked to restorative deep sleep rather than vivid dreaming. This pattern resembles what you see with stimulants more than what you’d expect from a “dream chemical.”
Animal research tells a complementary story. A 2024 study in rats found that 5-MeO-DMT, a close chemical relative of DMT, produced brain wave signatures that looked more like certain sleep states than like normal waking activity. The drug increased delta power in the hippocampus (a pattern associated with deep sleep) while decreasing theta power (associated with active exploration and REM).7Scientific Reports. 5-MeO-DMT induces sleep-like LFP spectral signatures in the hippocampus and prefrontal cortex of awake rats In other words, the drug pushed brain activity toward deep-sleep-like patterns, not toward the kind of activated brain state that accompanies vivid dreaming. These results are from a related compound in rats, so they do not map directly onto what endogenous DMT does during human sleep. But they add to the picture that DMT-family compounds and dream states do not line up the way the popular narrative suggests.
Dreams and Psychedelic Trips Look Similar on the Surface
Part of why the DMT-dream connection feels so intuitive is that the subjective experience of dreaming and the subjective experience of a psychedelic trip share real overlap. Both involve vivid visual imagery, emotional intensity, narrative distortion, and encounters with entities or situations that feel meaningful but don’t follow the logic of waking life. Researchers have formally compared the two states and confirmed genuine phenomenological similarities, but they’ve also identified key differences. The states diverge in perceptual input from the environment, clarity of consciousness, and metacognitive abilities: roughly speaking, in a dream you usually don’t know you’re dreaming, while on DMT you typically retain some awareness that you’ve taken a drug.8PubMed Central. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
The resemblance is interesting and worth studying, but resemblance is not causation. Two experiences can look alike without sharing a chemical trigger. Lightning and static electricity both produce sparks, but they arise from very different conditions. Dreaming involves a well-characterized set of neurological processes: the brainstem’s REM-generating circuits, acetylcholine surges, cortical activation with simultaneous muscle paralysis, and selective deactivation of prefrontal areas responsible for logical oversight. These mechanisms explain the weirdness of dreams without needing to invoke a psychedelic compound, and they are supported by decades of sleep research.
REM Intrusion Offers a Better Explanation for Extreme Experiences
One of the strongest motivations for the DMT hypothesis was to explain near-death experiences (NDEs): the tunnels of light, the sense of leaving the body, the overwhelming peace. If DMT floods the brain at death, the thinking went, it could account for all of that. But a simpler and better-supported explanation involves REM intrusion, the leaking of REM-sleep processes into wakefulness. A study in Neurology found that REM intrusion during wakefulness is a frequent normal occurrence, that it underlies other known clinical conditions, and that the specific elements of near-death experiences can be explained by it. People who report NDEs may have arousal systems that predispose them to REM intrusion in the first place.9PubMed. Does the arousal system contribute to near death experience?
REM intrusion can produce the visual hallucinations, feelings of bodily dissociation, and intense emotional experiences that people describe during cardiac arrest or other crises. It doesn’t require any special chemical release. The brain’s dream-generating machinery simply misfires at the wrong time. This doesn’t rule out every possible role for endogenous DMT, but it eliminates the strongest argument for the hypothesis by providing a well-documented alternative mechanism.
If Not Dreaming, What Might Endogenous DMT Actually Do?
The brain clearly makes DMT for some reason. Evolution tends not to maintain biosynthetic pathways for compounds that serve no function at all. So if DMT isn’t there to generate dreams, what is it for? One promising line of research focuses on the sigma-1 receptor, a protein that acts as a molecular chaperone inside cells. DMT binds to sigma-1 receptors, which regulate ion channels and modulate cellular stress responses. This is a different mechanism from the serotonin 5-HT2A receptor binding that produces psychedelic effects at high doses.10PubMed Central. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor
In 2016, researchers demonstrated that DMT acting through the sigma-1 receptor significantly increased the survival of human cortical neurons and immune-like brain cells under severe oxygen deprivation. The effect was robust and appeared to work independently of the usual hypoxia response pathways.11PubMed Central. The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells The researchers speculated that endogenous DMT may be generated during situations of stress, helping to protect brain tissue from damage when oxygen supply drops. This would make DMT less of a dream chemical and more of a cellular emergency responder, a neuroprotective agent deployed when cells are in trouble.
This reframing is arguably more interesting than the dream hypothesis, because it gives endogenous DMT a concrete, testable function that actually matches its trace-level concentrations. You don’t need psychoactive amounts of a compound to influence cellular survival pathways. A molecule that works at the sigma-1 receptor as a stress modulator could be biologically meaningful at the exact low concentrations that have been measured in living brains, without needing to reach the much higher levels required to activate serotonin receptors and produce hallucinations.
Why the Myth Persists
The DMT-dream idea has a kind of narrative perfection that makes it hard to dislodge. It connects ancient mystical traditions about the pineal gland to modern psychedelic pharmacology, wraps birth, death, and nightly dreaming into a single elegant mechanism, and gives people a materialist explanation for transcendent experiences. That’s a compelling story, and compelling stories survive even when the data doesn’t support them.
There’s also a measurement problem that leaves just enough ambiguity for believers to hold on. Nobody has continuously monitored DMT levels in a human brain during sleep, because doing so would require invasive sampling that no ethics board would approve for a healthy person. All we have are snapshot measurements from animal models and indirect reasoning from human pharmacokinetics. Proponents can always say “maybe it happens in a way we haven’t measured yet,” and technically they’re right that the question hasn’t been definitively closed by a single experiment. But the burden of evidence is on the hypothesis, and every piece of relevant data, including the concentrations, the enzyme kinetics, the REM-suppressing effects of administered DMT, and the available alternative explanations for dream phenomenology, points away from it rather than toward it.
The Transmethylation Connection
The fascination with endogenous DMT as a cause of altered mental states has a longer history than most people realize. In the 1950s, decades before Strassman’s work, researchers proposed the “transmethylation hypothesis” of schizophrenia. The idea was that abnormal methylation in the brain might produce psychotomimetic compounds, including methylated indoleamines like DMT, which could cause psychotic symptoms. Years of intensive research failed to find evidence supporting the theory.12ScienceDirect. The transmethylation hypotheses of schizophrenia re-evaluated The hypothesis was eventually abandoned, but it illustrates a recurring pattern in how scientists and the public think about endogenous psychedelics: people keep hoping that trace amines in the brain will explain dramatic mental phenomena, and the data keeps falling short.
That said, the failure of the transmethylation hypothesis didn’t mean endogenous DMT was biologically irrelevant. It just meant that the compound wasn’t doing what people wanted it to do. The same lesson applies to the dream hypothesis. The brain makes DMT. It likely serves a purpose. That purpose is probably not generating your dreams, and it’s almost certainly something less cinematic but more scientifically interesting than a built-in psychedelic trip switch.
What Would It Take to Settle the Question
For the DMT-dream hypothesis to graduate from speculation to science, researchers would need to show a few specific things. First, they would need to demonstrate that DMT levels in the brain rise sharply during REM sleep, not just that DMT is detectable at baseline. Second, the rise would need to reach concentrations high enough to activate serotonin 5-HT2A receptors, which mediate the psychedelic effects. Third, blocking that rise, whether through enzyme manipulation or receptor antagonism, would need to alter dreaming in measurable ways. None of these steps have been accomplished, and the first alone would require either a major advance in non-invasive neurochemical imaging or an invasive study in animals with simultaneous sleep-stage monitoring and real-time DMT measurement.
The 2019 University of Michigan study that confirmed DMT biosynthesis in rat brains is the closest anyone has come to the first step, and even that study did not measure DMT levels across sleep-wake cycles.2Scientific Reports. Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain The researchers did find that cardiac arrest in rats caused a spike in brain DMT levels, which is tantalizing for the near-death-experience angle but says nothing about ordinary sleep. Until someone designs and executes these experiments, the honest answer remains that the DMT-dream hypothesis is an unsubstantiated claim dressed in the trappings of neuroscience, appealing but unsupported by the data that actually exists.